Amgen Inc.

Abbott Laboratories Corporation

Tularik Limited

Amgen Sf, LLC

Beijing Xuanyi Pharmasciences Co., Ltd.

Reiley Pharmaceuticals, Inc.

Xiaoqi Chen

Jeffrey Thomas Mihalic

Zice Fu

Julio Cesar Medina

Jeffrey Deignan

Zhihua Ma

David John Kopecky

Xiaodong Wang

Richard V Connors

Julie Anne Heath

Steven H Olson

Xiaohui Du

Lawrence R McGee

Jonathan B Houze

Paul John Dransfield

Vatee Pattaropong

Su-Jen Lai

Ning Chen

Nobuko Nishimura

Frank Kayser

Matthew R Kaller

Leping Li

Alan C Cheng

Daniel B Horne

Mikkel V Debenedetto

Kevin Chao Yang

Ted Charles Judd

Jason A Duquette

Gayathri Swaminath

Simon J Hedley

Daniel W Norbeck

Pingchen Fan

Wen-Chen Yeh

Aarif Yusuf Khakoo

Yinhong Chen

Hing L Sham

Juan Carlos Jaen

Darin J Gustin

Robert P Farrell

Dale J Kempf

David A Betebenner

Michael G Johnson

Zhihong Li

Thomas R Herrin

Kang Dai

Jiwen Liu

Daniel A Dickman

Lawrence Kolaczkowski

James S Harvey

Ketan M Patel

Stephen L Condon

Arthur J Cooper

Eric J Stoner

Michael W Gribble, Jr

Jay Patrick Powers

John A Flygare

Daqing Sun

Xuelei Yan

Timothy David Cushing

Yosup Rew

Felix Gonzalez Lopez De Turiso

Brian M Fox

Michael D Bartberger

John Eksterowicz

Hilary Plake Beck

Ana Zurisadai Gonzalez Buenrostro

An-Rong Li

Steven M Hannick

Daniel J Plata

Jih-Hua Liu

Joel McIntosh

Mike Elias Lizarzaburu

Jiasheng Fu

Yihong Li

Philip M Roveto

Dustin L McMinn

Ming Yu

Jonathan Dante Low

Xi Chen

Xianghong Wang

Brian Stuart Lucas

Yuntao Song

Yingcai Wang

Sarah Lively

Lars V Heumann

Jian Zhang

XianYun Jiao

Xin Huang

SuJen Lai

Jiang Zhu

Mark A Reiley

Matthew Irvine Brown

Laman L Alani

Soumojeet Ghosh

Jien-Heh J Tien

Kevin Yang

Dilip Kaul

John M Lipari

Michael J Schmitt

The present disclosure relates to a compound of formulae (I) or (II), or a pharmaceutically acceptable salt, a solvate, a hydrate thereof, a pharmaceutical composition comprising a compound of formulae (I) or (II), and use thereof, wherein various Markush groups are as described herein.

Cyclic di-nucleotides as stimulator of interferon genes modulators

The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (A) or formula (B), and any subgenera thereof, and use of said compounds and compositions thereof, wherein R, R, R, R, R, R, X, X, Y and n are described herein. 

Substituted pyrimidines as CDK4/6 inhibitors

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Methods of treating heart failure include administering to a subject having heart failure an effective amount of a triazole compound that is an agonist of the APJ receptor, a pharmaceutically acceptable salt of the compound, or a mixture thereof. Compounds particularly useful in such methods are provided herein.

Methods of treating heart failure

The present disclosure provides platinum-containing conjugates that selectively target and kill tumor/cancer cells. The conjugates contain a moiety that selectively targets COX-2, which is overexpressed by a broad range of tumor/cancer cells.

COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

Growing community of inventors

Palo Alto, CA, United States of America

Xiaoqi Chen